OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
Completed
Sanofi
Phase 3
2003-08-01
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational
study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction)
randomized within 24 hours of the onset of symptoms.
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
Completed
GlaxoSmithKline
Phase 3
2003-08-01
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational
study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction)
randomized within 24 hours of the onset of symptoms.
Which Therapy for Acute Heart Attacks? (The WEST Study)
Completed
Eli Lilly and Company
Phase 2/Phase 3
2003-07-01
In the setting of acute myocardial infarction (heart attacks), the principle objective of the
WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies.
The first is using medical (drug) therapy alone with standard care. The second strategy is
identical medical (drug) therapy as the first group combined with early heart catheterization
(within 24 hours) for angiography and if required, intervention. The third treatment strategy
is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty.
WEST patients will be enrolled at first medical contact (using emergency medical services,
e.g. ambulance) if possible or through Emergency Departments in participating health care
facilities.
Which Therapy for Acute Heart Attacks? (The WEST Study)
Completed
Hoffmann-La Roche
Phase 2/Phase 3
2003-07-01
In the setting of acute myocardial infarction (heart attacks), the principle objective of the
WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies.
The first is using medical (drug) therapy alone with standard care. The second strategy is
identical medical (drug) therapy as the first group combined with early heart catheterization
(within 24 hours) for angiography and if required, intervention. The third treatment strategy
is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty.
WEST patients will be enrolled at first medical contact (using emergency medical services,
e.g. ambulance) if possible or through Emergency Departments in participating health care
facilities.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
